The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
November 25th 2024
Recent studies suggest limited benefit post-myocardial infarction for patients with preserved heart function, prompting potential updates to treatment guidelines and reconsideration of long-term use.
Oncology Overview: Akynzeo for Chemotherapy-Induced Nausea and Vomiting
February 23rd 2022Combination netupitant and palonosetron capsules/fosnetupitant and palonosetron for injection (Akynzeo) is indicated to prevent acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy.
Read More
Study: Vaccinated Patients Less Likely to Need Critical Care During Omicron Surge
February 21st 2022During the period in which Omicron was the dominant variant, the researchers found that fewer patients died while hospitalized compared with those admitted when the Delta variant was dominant.
Read More
Data Show the Rate of Acquiring COVID-19 During Hospital Stay Is Significantly Lower Than Expected
February 21st 2022Jeff Trinkl, MD, director of clinical informatics at Epic, and Caleb Cox, data scientist at Epic, explain that only about 1.8% of patients contracted COVID-19 during a hospital stay at the highest peak of cases in December 2020.
Watch
Daily Medication Pearl: Finerenone (Kerendia)
February 21st 2022Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease.
Read More
Expert: Reproduction, Sexual Health Have Not Yet Been Separated When Discussing Women's Health
February 17th 2022Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some of the common practices for the treatment of hypoactive sexual desire disorder in women and men.
Watch
Adding Dalpiciclib to Fulvestrant Prolongs Survival in HR–positive, HER2-negative Breast Cancer
February 17th 2022Dalpiciclib added to fulvestrant (Faslodex) was found to significantly prolong progression-free survival compared with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Read More
Hyperimmune IVIG Plus Remdesivir Does Not Improve Outcomes in Patients Hospitalized With COVID-19
February 17th 2022The safety of an anti-coronavirus hyperimmune intravenous immunoglobulin may be influenced by whether an individual is able to naturally generate SARS-CoV-2-neutralizing antibodies.
Read More